Related Experiment Video
Updated: Aug 16, 2026

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
[Erythropoietin: new perspectives in treating cardiac insufficiency?]
Grazyna Snopek1, Agata Popielarz-Grygalewicz, Marek Dabrowski
1Kliniczny Oddział Kardiologii, Szpital Bielański w Warszawie. snopek@mp.pl
Abstract:
Erythropoietin, a hormone known to be a stimulator of erythropoiesis, is widely used in the treatment of anemia in patients with chronic renal failure. The latest experiments proved that it can also bring beneficial effects in patients with cardiovascular disease. It prevents cardiomyocyte apoptosis during myocardial infarction and can relieve disease symptoms in patients with congestive heart failure and anemia. Further experiments and clinical trials are necessary to investigate the pathophysiological mechanisms and clinical effects of this treatment.
More Related Videos
11:51Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
Published on: March 1, 2016
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Related Concept Videos
Pathophysiology of Cardiac Performance
Erythropoiesis
Erythropoiesis
Heart Failure VI: Adjunct Therapies
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Heart Failure II: Pathophysiology